Dual Targeting Of mTOR/IL-17A And Autophagy By Fisetin Alleviates Psoriasis-Like Skin Inflammation

dc.contributor.authorRoy, T.
dc.contributor.authorBanang-Mbeumi, S.
dc.contributor.authorBoateng, S.T.
dc.contributor.authorRuiz, E.M.
dc.contributor.authorChamcheu, R.-C.N.
dc.contributor.authorKang, L.
dc.contributor.authorKing, J.A.
dc.contributor.authorWalker, A.L.
dc.contributor.authorNagalo, B.M.
dc.contributor.authorKousoulas, K.G.
dc.contributor.authorEsnault, S.
dc.contributor.authorHuang, S.
dc.contributor.authorChamcheu, J.C.
dc.date.accessioned2026-11-02T13:24:13Z
dc.date.issued2023-01
dc.description.abstractPsoriasis is a chronic autoimmune inflammatory skin disorder characterized by epidermal hyperplasia and aberrant immune response. In addition to aberrant cytokine production, psoriasis is associated with activation of the Akt/mTOR pathway. mTOR/S6K1 regulates T-lymphocyte activation and migration, keratinocytes proliferation and is upregulated in psoriatic lesions. Several drugs that target Th1/Th17 cytokines or their receptors have been approved for treating psoriasis in humans with variable results necessitating improved therapies. Fisetin, a natural dietary polyphenol with anti-oxidant and anti-proliferative properties, covalently binds mTOR/S6K1. The effects of fisetin on psoriasis and its underlying mechanisms have not been clearly defined. Here, we evaluated the immunomodulatory effects of fisetin on Th1/Th17-cytokine-activated adult human epidermal keratinocytes (HEKa) and anti-CD3/CD28-stimulated inflammatory CD4 + T cells and compared these activities with those of rapamycin (an mTOR inhibitor). Transcriptomic analysis of HEKa revealed 12,713 differentially expressed genes (DEGs) in the fisetin-treated group compared to 7,374 DEGs in the rapamycin-treated group, both individually compared to a cytokine treated group. Gene ontology analysis revealed enriched functional groups related to PI3K/Akt/mTOR signaling pathways, psoriasis, and epidermal development. Using in silico molecular modeling, we observed a high binding affinity of fisetin to IL-17A. In vitro, fisetin significantly inhibited mTOR activity, increased the expression of autophagy markers LC3A/B and Atg5 in HEKa cells and suppressed the secretion of IL-17A by activated CD4+ T lymphocytes or T lymphocytes co-cultured with HEKa. Topical administration of fisetin in an imiquimod (IMQ)-induced mouse psoriasis model exhibited a better effect than rapamycin in reducing psoriasis-like inflammation and Akt/mTOR phosphorylation and promoting keratinocyte differentiation and autophagy in mice skin lesions. Fisetin also significantly inhibited T-lymphocytes and F4/80+ macrophage infiltration into skin. We conclude that fisetin potently inhibits IL17A and the Akt/mTOR pathway and promotes keratinocyte differentiation and autophagy to alleviate IMQ-induced psoriasis-like disease in mice. Altogether, our findings suggest fisetin as a potential treatment for psoriasis and possibly other inflammatory skin diseases.en
dc.identifier.urihttps://doi.org/10.3389/fimmu.2022.1075804
dc.identifier.urihttps://space.uenr.edu.gh/handle/123456789/134
dc.language.isoen
dc.relation.ispartofFrontiers in Immunology, Volume 13, Article 1075804
dc.subjectautophagy
dc.subjectfisetin
dc.subjectpsoriasis
dc.subjectAkt/mTOR and IL-17A
dc.subjectrapamycin
dc.subjecttopical administration
dc.subjectpsoriasis-like skin inflammation
dc.subjectkeratinocytes RNA-sequencing
dc.titleDual Targeting Of mTOR/IL-17A And Autophagy By Fisetin Alleviates Psoriasis-Like Skin Inflammationen
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023 - Dual targeting of mTOR IL-17A and autophagy by fisetin alleviat.pdf
Size:
11.52 MB
Format:
Adobe Portable Document Format

Collections